Scribe Therapeutics confirmed readiness to test its first CRISPR‑based therapeutic in humans this summer, moving the company’s novel CRISPR enzyme platform from preclinical development toward clinical proof‑of‑concept. The trial will be the first test of Scribe’s engineered editors in patients and marks a milestone for programmable nuclease therapeutics. Complementing that clinical momentum, researchers reported therapeutic potential for the CRISPR–Cas3 system in Nature Biotechnology, demonstrating broader genome‑editing strategies beyond Cas9 that may enable permanent reduction of pathogenic gene expression. Together the announcements underscore accelerating diversity in genome‑editing modalities and near‑term translational paths for new editing enzymes.